|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||199.39 - 200.40|
|52 Week Range||164.80 - 202.04|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Some investors are eagerly betting on mid-cap ETFs.
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).